Real-world impact of anti-HER2 therapy-related cardiotoxicity in patients with advanced HER2-positive breast cancer.

Ciara ConduitR H de BoerS LokP GibbsL MalikZ LohB YeoS GreenbergB DevittJ LombardM NottageIan M CollinsJ TorresM NolanL Nott

Published in: Asia-Pacific journal of clinical oncology (2020)

Therapy-related cardiotoxicity is an uncommon complication of anti-HER2 therapy in the real world setting. Cardiac toxicity resolved in the majority of affected patients, and further anti-HER2 therapy was administered without recurrence of cardiac issues. Our data suggests anti-HER2 therapy can be safely given in routine care, even in patients with risk factors for toxicity.

Keyphrases

end stage renal disease
chronic kidney disease
oxidative stress
positive breast cancer
palliative care
heart failure
stem cells
mesenchymal stem cells
ejection fraction
machine learning
chronic pain
prognostic factors
big data
replacement therapy
patient reported